Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| jRCT2031210168 | Registry Identifier | jRCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine.
The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for long-term side effects of the COVID-19 vaccine. This will be from 28 days to 12 months after the second vaccination of the COVID-19 vaccine.
The number of visits to the clinic will depend on the clinic's standard practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 Vaccine Intramuscular Injection 0.5 milliliters (mL) | COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 Vaccine | Biological | COVID-19 Vaccine Intramuscular Injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Serious Adverse Events (SAE) | An SAE is defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. | 11 months (From 28 days to 12 months after the second vaccination) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants who Take COVID-19 Pathogen (Severe Acute Respiratory Syndrome coronavirus [SARS-CoV-2]) Test during the Study | 11 months (From 28 days to 12 months after the second vaccination) | |
| Number of Participants who Developed COVID-19 during the Study |
Not provided
Inclusion Criteria:
Participants who have participated in the preceding cohort study and has subsequently provided written consent to participate in this study.
Exclusion Criteria:
None
Not provided
Not provided
Not provided
Not provided
The population of this survey are vaccinated participants who meet the inclusion/exclusion criteria.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Moderna selected site | Tokyo | Japan |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086663 | COVID-19 Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
| 11 months (From 28 days to 12 months after the second vaccination) |
| Number of Participants Who Have Severe COVID-19 Infection during the Study Evaluated by Investigator | Number of participants who have severe COVID-19 infection during the study evaluated by investigator will be reported. Investigator will evaluate the severity of COVID-19 infection with COVID-19 information entered in the case report form in reference to "Guidance for Clinical Practice of Novel Coronavirus Infection (COVID-19)". | 11 months (From 28 days to 12 months after the second vaccination) |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |